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The endovascular revolution stopped at the
carotid bifurcation . . . or did it?
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MAs the Society for Vascular Surgery (SVS) approaches
its 70th anniversary, I am awed and humbled at the great
privilege, if somewhat improbable circumstance, of leading
the nation’s oldest and largest society devoted to the care of
patients with vascular disease. My term has been both
rewarding and certainly the assemblage of a presidential
address has at times daunted me. I have been steered by the
wisdom of Presidents past; I learned much from Dr Shu-
maker’s fascinating history of the first 50 years of the SVS,1
and I am pleased to report that in follow-up of our 50th
anniversary meeting, Drs Jimmy Yao and Norm Rich are
leading an effort to chronicle our past 20 years.
In deciding on fact or philosophy for this address, I
have fundamentally come to the position that I am first and
foremost a vascular surgeon and accordingly, my topic this
morning, on carotid atherosclerosis, is one of the core
components of vascular surgical practice coming into the
modern era shortly after the founding of the SVS in 1947.
Furthermore, there has been much activity in the carotid
arena of late; some of this is actually science, much is not.
Also, in such Presidential addresses, tradition must be
served, and the great tradition of our society is entwined
with certain Boston Pioneers and with the evolution of
vascular surgery at the Massachusetts General Hospital
(MGH), where I have had the great privilege to spend
essentially my entire professional career. From the vision of
its 31 Founding Members, the SVS has evolved in stature,
size, and influence as among the nation’s pre-eminent
medical professional organizations. Our recent history has
solidified SVS as the representative organization for all
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1748ascular surgeons, and today, we stand nearly 4000 mem-
ers strong, with an annual budget of some 7 million
ollars, and an effective force of nearly 300 of our members
arrying out the SVS mission in some 30 different councils
nd committees. In particular, I owe a great deal to my
olleagues on the SVS Executive Committee who provided
e with both wisdom and the sometimes needed temper-
nce over the past year.
Customary in a Presidential address is the acknowledg-
ent of the many in my personal and professional life that
ade it possible for me to become your 66th president. My
rofessional evolution at the MGH in Boston began only
fter disillusionment at the prospect of becoming a cardiac
urgeon. I went to medical school convinced I would be a
ardiac surgeon. I was only dissuaded during my subintern-
hip on cardiac surgery. Accordingly, when I had the great
ortune to do a subinternship in vascular surgery at the
GH under the tutelage of my professional godfather, Dr
. Clement Darling, Jr, MD, in September of 1976, I
iscovered the specialty that seem to suit me so well as the
ascular surgeon was the expert in the diagnosis, clinical
ecision-making, and execution of the surgical treatment of
atients afflicted with vascular disease. Perhaps even more
mpressive, at the time, no other medical or surgical spe-
ialty either knew anything about vascular disease nor had
ny interest in being involved in same. To be sure, a
hangri-La of sorts, but of course, not reality today.
HE HISTORY OF VASCULAR SURGERY AT
GH AND THE FOUNDING OF THE SVS
The history of vascular surgery at the MGH is inti-
ately entwined with the beginning days of the SVS.
rthur Allen, MD (Fig), was the first vascular surgeon at
he MGH. He was, by all accounts, a surgeon for all seasons
ith the wide range of interests in surgery that crossed
astrointestinal, endrocrine, and vascular surgery. Influ-
nced to a degree by John Homans, also in Boston, he was
riting on periarterial sympathectomy in the 1920s in the
riginal Boston Medical and Surgery Journal, which would
ltimately become the New England Journal of Medicine.
llen was appointed Chief of the Vascular Clinic at the
GH in 1928, the first such clinic of its kind in the US. Its extraordinary to read some of his early work, such as his
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Volume 56, Number 6 Cambria 1749report on the use of typhoid vaccine injection to augment
the microcirculation in young people with gangrene, likely
secondary to what we would refer to today as thromboangi-
nitis obliterans.2 This paper was read before the annual
meeting of the American Medical Association in 1928; it
contributed to Allen’s national stature as a leader in vascular
disease management. Allen spent a large part of his profes-
sional career investigating the prophylaxis of pulmonary
embolism and was the first to promulgate ligation of the
superficial femoral vein in the prevention of pulmonary
embolism. His paper, on the MGH series of such opera-
tions, delivered before the American Surgical Association in
1943,3 positioned him as one of the national leaders in an
effort to initiate a surgical professional society devoted to
vascular disease management. Accordingly, he was one of a
group of six individuals who held an initial organizational
meeting in December of 1945 at the Southern Surgical
Association; a follow-up meeting occurred the following
July, and the SVS was launched. The initial SVS scientific
meeting was held on the Steel Pier in Atlantic City, New
Jersey, in June of 1947. Allen, who would go on to be the
second president of the SVS, succeeding Alton Ochsner,
chaired the program committee of that first meeting; the
very first paper at the very first SVS meeting was delivered
by one Robert R. Linton, MD, whose name is forever
associated with the origins of modern vascular surgery,
Fig. Arthur W. Allen, MD (1887-1958). Dr Allen established a
vascular clinic at Massachusetts General Hospital (1928) and was
the second Society for Vascular Surgery president.both in Boston and across the nation. Linton, in turn, had watapulted to national fame based on his work with lower
xtremity venous disease and his sentinel work published in
938, which was the initial description of the importance of
he ligation of incompetent perforating veins in the preven-
ion of the postthrombotic syndrome.4 Accordingly, Lin-
on was well positioned to initiate modern arterial recon-
tructive surgery at the MGH right around the year I was
orn; his contributions to vascular surgery were many, and
is ninth SVS presidential address delivered in 1955 was, in
act, the first of the SVS Presidential addresses to deal with
irect arterial reconstructive surgery. In the twilight of his
areer, Dr Linton was invited to give the prestigious
oman’s lecture before the SVS, and his topic was John
omans’ impact on Venous Surgery. Interestingly, most of
his address centered on the effectiveness of the methods
inton developed (ligation of incompetent perforators), as
pposed to radical soft tissue excision and skin grafting
spoused by Homans!5 Linton was a master technical sur-
eon and performed the first successful direct repairs of
oth abdominal aortic aneurysms and autogenous veins
ypass surgery in New England. His monumental Atlas of
ascular Surgery, published in the early 1970s, was for
any years a vascular surgery bible and a prized possession
f graduating MGH Vascular Surgical Trainees. When I
eceived mine, I was the initial Robert R. Linton Research
ellow. The circle is now complete with the inauguration of
he Robert R. Linton, MD, professorship in Vascular and
ndovascular Surgery at the Harvard Medical School and
he Massachusetts General Hospital. To be the first incum-
ent of this chair is for me the stuff that dreams are made of.
inton’s protégé and partner, joining him in practice at the
GH in 1960 after a two-year fellowship with Dr De-
akey, was Dr R. Clement Darling, Jr, who was my princi-
le teacher of vascular surgery. He opened his practice to
e in the evolution of our central aortic practice. A few
ears ago, as president of the New England Society for
ascular Surgery, I had the opportunity to recount in detail
r Darling’s many contributions to vascular surgery.6 Dr
arling was reporting large series of femoropopliteal vein
ypass grafts before the SVS in the mid-1960s; he invented
nd promulgated the lower extremity arterial noninvasive
echnique that is widely used across the world today in a
entinel report delivered before the SVS in 1971.7 To Dr
arling, I owe an incredible debt, and yes, he was the father
f our current SVS treasurer Dr R. Clement Darling, III,
rom Albany, New York. Although by proxy, Dr E. Stanley
rawford was both my hero and had a profound influence
n the development of my aortic surgery practice. Dr
rawford was chief resident at the MGH in 1955, and
erhaps the greatest aortic surgeon who ever lived. His
utographed picture, which hangs in my office, is signed
best wishes and highest esteem.” By proxy, I mean that Dr
rawford’s son, John, who joined him in the authorship of
he monumental Crawford’s Atlas of Aortic Surgery, was
hief resident with me at the MGH in 1984. Dr Crawford,
ur 42nd president, delivered the Homans lecture in 1991
hrough his son, John, because at that point, Dr Crawford
as disabled with a stroke; his address, entitled “Heroes in
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December 20121750 CambriaVascular Surgery,” was one of the more inspiring things I
have ever heard at a scientific meeting.8
My colleagues in the division of vascular and endovas-
cular surgery at the MGH are my special family. They are
the reason I find it so much fun to go to work every day.
Our many vascular fellows over the years have contributed
to my professional development in a way that they could
never know. They have had to endure my intensity and my
insistence on perfection passed down from Dr Linton, but
they annually renew me with their accomplishments and
their own individual outstanding stories.
PERSONAL HISTORY
You have heard elements of my personal story from
President-Elect Gloviczki. Dr Sanjiv Chopra, who has lec-
tured all over the world on leadership, indicates that all
leaders have a story to tell.9 I hope you will indulge me a
few moments to hear mine. As a small child, I came under
the influence of John Caccamo, my maternal grandfather.
He was an outstanding, if typical, representative of the
great wave of immigrants who sought a better life in
America. Coming to this country from Sicily as a desper-
ately poor 16-year-old in 1904 with little more than an
address of certain relatives who settled in Brooklyn, he had
to wait 3 weeks in confinement at Ellis Island to be sure that
he did not bring tuberculosis into the country. He was a
man of great faith, if somewhat stern, but embodied that
outstanding quality of the immigrant generation – a fierce
tenacity to succeed. He started the family business – John’s
Meat Market – the butcher shop establishment, which
operated for some 70 consecutive years in Elizabeth, New
Jersey, where I spent my formative years and where later,
my father would teach me many things, including how to
carve a side of beef! My father was a perfect example of what
Tom Brokaw and Stephen Ambrose termed “the greatest
generation this country has ever produced.” Like so many
of his generation, many of his prime years were spent in the
military service of his country. As a navigator/bombardier
on a B-25 in the horror of the Pacific theater in World War
II, he was witness to history on August 9, 1945, when he
saw the second atom bomb explode over Nagasaki, effec-
tively ending World War II. His influence on me was
enormous, but of course it was some years before I recog-
nized this; he taught me humanism and kindness, which I
hope to have brought to the care of the thousands of
patients I have had the privilege to care for over the past 30
years. In each person’s development, there are profound
influences, usually early in life, and mine was working
side-by-side with my father in the butcher shop beginning
when I was 12 years of age. In his book Outliers, Malcolm
Gladwell examines the careers of some outstandingly suc-
cessful people and, in a very learned treatise, ascribes suc-
cess more to circumstance than to brilliance.10
The people who stand before kings may look like they did
it all by themselves . . . but, in fact, they are the beneficia-
ries of hidden advantages and extraordinary opportunities
and cultural legacies that allow them to work hard and imake sense of the world in ways others cannot. It makes a
difference where and when we grew up. The culture we
belong to and the legacies passed down by our forebears
shape the patterns of our achievement in ways we cannot
begin to imagine.
Accordingly, I am here before you today as SVS presi-
ent because my father took me as a young boy to work
ith him in the butcher shop. It’s as simple as all that. My
ife, Chris, and my five children have sustained me these
ast 30 years and continue to do so. They never asked, “Do
ou have to make rounds today?” My first son, Andy, was
orn when I was an intern, and now having come full circle,
y wife, Chris and I experienced the unbelievable joy of
ur first grandchild, baby Sadie, born 18 months ago at the
GH and timed perfectly in between cases! I have had
any blessings in life, but being baby Sadie’s pop-pop is
ust about the best of them. While supporting me, my wife
nd children have also kept me grounded. Let me give you
n example; my second son, Jay, when he was 16, had a
ood way of putting it. I had gone to look at a job in
leveland at some point in midcareer and was chatting
bout it with the family. My son Jay’s comment was, “Dad,
e want you to know that if you take that job in Cleveland,
ou can call home anytime you want.” Needless to say, I
tayed in Boston.
VS INITIATIVES
While I intended to stick to topic, I would be remiss if
failed to report on some of our major developments in the
VS this year, and many of these are in the carotid sphere,
hus the rationale for focusing on the carotid disease debate
oday. Now about a year and a half old, the Vascular
uality Initiative (VQI) has positioned our society and our
rofession as the leaders in quality improvement efforts
elative to vascular procedures. SVS leadership over the past
everal years felt it entirely appropriate and vitally important
or SVS to be in a leadership position in such activities.
odeled on the highly successful and now 9-year-old
ascular study group of New England, the VQI has several
istinct components, as recently reviewed by our medical
irector, Jack Cronenwett, in the Journal of Vascular Sur-
ery.11 These include an Agency for Healthcare Research
nd Quality-certified Patient Safety Organization, which
ncidentally, was the very first medical profession society to
old such designation, regional quality groups, and a ro-
ust procedural data platform with our corporate partner
ho provides the web-based data platform. This effort has
rown exponentially in the past 16 months, and we cur-
ently have approximately 200 hospitals and over 50,000
rocedures in the database. I encourage all SVS members to
oin in the VQI effort; it is an important vehicle to advance
ur specialty and benchmark your practice.
A particular effort during my presidency has been to
acilitate one of our strategic goals articulated in 2008,
amely an increase in the number of newly trained vascular
urgeons. Both projections of the total numbers of practic-
ng vascular surgeons, the age demographics of our work-
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Volume 56, Number 6 Cambria 1751force, and the actual data in our fellowship training pro-
grams reveal the relatively flat trajectory in the vascular
surgery workforce. While many surgical subspecialties have
seen a decrement in the pool of qualified applicants for
training programs, the now 5-year-old 0-5 integrated vas-
cular residency training paradigm has been fabulously suc-
cessful and is among the Accreditation Council for Gradu-
ate Medical Education’s most avidly sought subspecialty
training programs. Bringing quality vascular care to all
types of practice settings can only be accomplished by
increasing the supply of vascular surgeons. We initiated a
vascular fellowship development task force over the past
year. I am greatly indebted to the vascular surgery leaders
who joined me in this task force: Ronald Dalman, John
Eidt, Vivian Gahtan, Jeffrey Jim, Craig Kent, Michel Ma-
karoun, and Jon Matsumura. Our committee was com-
posed of representatives from different geographic regions
across the country, and we assembled a list of potential
practices and hospitals wherein vascular residencies and/or
fellowships could be developed. I am pleased to announce
that as a product of this task force, SVS has now made
available to prospective fellowship sites a series of programs,
tools, and mechanisms to foster the development of new
vascular residencies and/or fellowships. These are in the
form of a handbook for new fellowship directors, which
includes strategies for dealing with department chairs and
hospital administrators, a reference list of current fellowship
directors to serve as mentors and facilitators, and an SVS-
sponsored consultant who will travel to potential sites to
help in program development.
DEVELOPMENTS IN THE CAROTID SPHERE
While all vascular surgeons are aware of the firestorm
referable to carotid angioplasty and stenting (CAS) versus
carotid endarterectomy (CEA), certain temporal events
have caused both the debate and the technology into a
waxing and waning posture in recent years. Listed in the
Table are some of the important events more recently,
which makes a consideration of the carotid paradigm an
appropriate topic for today’s meeting. After the publica-
tion of a number of European-based randomized trials
clearly implicating CEA as the preferred treatment (vs
Table. Carotid arena: Recent notable events
● February/June 2010: Presentation/publication of CREST52
● 2011: Publication of five international practice guidelines
● February 2011: Multispecialty ACC/AHA77
● September 2011: SVS updated practice guidelines16
● October 2011: SVS Clinical Research Council convenes
clinical research priorities Retreat17
● January 2012: CMS convenes MEDCAC on carotid
atherosclerosis18
ACC/AHA, American College of Cardiology and the American Heart Associ-
ation; CMS, Centers for Medicare and Medicaid Services; CREST, Carotid
Revascularization Endarterectomy versus Stenting Trial; MEDCAC, medical
evidence discovery and coverage analysis group meeting; SVS, Society for
Vascular Surgery.CAS) in the management of, in particular, symptomatic patients, the medical community eagerly awaited comple-
ion of the Carotid Revascularization Endarterectomy ver-
us Stenting Trial (CREST).12-14 Both practitioners and
egulatory agencies would consider this large well-conducted
rial as a sentinel event in the carotid sphere. Soon after
ublication of the CREST study in mid-2010, these data
ere incorporated into the promulgation of some five
ifferent international practice guidelines published in
011, which were recently compared in a short Journal of
ascular Surgery review article upon which I had the privilege
o comment.15 Doubtless you are familiar with the SVS up-
ated practice guidelines that contain the best available/most
eclarative/evidence-based management guidelines for pa-
ients with carotid stenosis.16 Also, in 2011, the SVS Clin-
cal Research Council convened a clinical research priorities
etreat with 40 experts gathering to hear presentations and
therwise vote in hierarchical fashion on the important
linical research questions in our practice. As a product of
hat meeting, SVS identified clinical management of
symptomatic carotid stenosis as its number one clinical
esearch priority. This is not to be interpreted as a retribu-
ion of any component of the updated 2011 SVS practice
uidelines referable to carotid disease, but rather an ac-
nowledgment that further research in characterizing the
ature and risk of asymptomatic carotid stenosis is certainly
n order. Details of the research priorities retreat will soon
e published in JVS.17
In anticipation of a reconsideration by Centers for
edicare and Medicaid Services (CMS) of the National
overage Determination (NCD) for CAS, the SVS board
f directors by vote of 21 of its 22 members in June 2011
repeated in identical manner and result at the June 2012
oard of Directors meeting), voted against any change in
VS position relative to the current CMS coverage deter-
ination for CAS. In additional, and at the invitation of
MS, SVS submitted (in May 2012) a detailed position
tatement opposing any change in the current NCD rela-
ive to CAS. Although an application was made to CMS, it
as deferred when CMS instead convened a medical evi-
ence discovery and coverage analysis group meeting
MEDCAC) in January of this year. A MEDCAC meeting
s different than a reconsideration of coverage and consists
f a panel of medical experts who hear both invited testi-
ony and then at-large testimony from interested stake
olders. Given the importance of carotid disease as a core
omponent of vascular surgery practice, SVS had a very
ctive role at the January MEDCAC, offering a variety of
ral presentations and submitting a comprehensive docu-
ent addressing the meeting’s seven research questions,
nd this material was recently published in the Journal of
ascular Surgery.18
AROTID DISEASE AND STROKE: THE
UNDAMENTALS
The supporting research data in the carotid sphere
ould occupy a textbook; indeed, the Rutherford textbook
f vascular surgery contains some 11 chapters and 200
ages devoted to the management of cerebrovascular dis-
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Homans’ lecture, delivered in 1995 at the 50th anniversary
meeting, has there been comprehensive treatment of the
carotid story from this podium. Dr Thompson’s wonderful
treatise, which should be read by all students of carotid
surgery, closed with an admonition referable to CAS . . .
and I quote, “mortality and stroke rates are not acceptable
when compared to carotid endarterectomy.”19 He went on
to quote Osler, “. . .the foolishness of yesterday has be-
come the wisdom of tomorrow.” As I will review with you,
15 years hence, the clinical realities as reviewed in SVS
practice guidelines have not changed much.
I have chosen to outline this topic beginning with
fundamentals of pathogenesis, and proceeding to natural
history data before considerations of the efficacy and safety
of intervention. What I refer to as the fundamentals of
pathology and pathophysiology, while well known to most
vascular surgeons, is important to delineate as a foundation
for clinical decision making in carotid disease. It is my belief
that such considerations are not in the knowledge base of
some who seek to manage carotid disease. Any prophylactic
treatment, whether it be repair of an abdominal aortic
aneurysm or carotid endarterectomy for asymptomatic ca-
rotid stenosis is, of course, predicated on a thorough
knowledge of the natural history of the lesion without
treatment, and an important consideration in the carotid
sphere is the role and/or limitations of modern medical
therapy in the management of those with asymptomatic
carotid stenosis. Where we have come with both CEA and
where we hope to potentially go with CAS are important
elements of the debate, as is, of course, the available com-
parative data referable to CEA and CAS.
The father of carotid surgery was, in fact, not a surgeon
at all. Rather, the original description of the relationship
between carotid disease and its causative role in ipsilateral
hemispheric stroke was delineated by C. Miller Fisher, MD,
a stroke neurologist who spent his career at the MGH. In
1949, the preponderance of thought was that ischemic
stroke was largely related to vasospasm and/or spontane-
ous thrombosis of the middle cerebral artery. In dissecting
brains of patients who had died of stroke, Miller Fisher
made the observation that there was no trace of vascular
blockage in the middle cerebral artery. He took this appar-
ent incongruity during further investigations as a stroke
fellow at the Montreal Neurological Institute. He recorded
carefully elements of histories of patients who had severe
hemispheric stroke, noting that a history of transient mon-
ocular blindness on the side contralateral to the stroke was
frequently obtained. One such patient, whom he had ques-
tioned carefully, died of a rectal carcinoma, and Miller
Fisher pushed to perform an autopsy, including the ipsilat-
eral carotid artery. One of my favorite papers in the realm of
carotid surgery was published by Miller Fisher in 1951 (the
year I was born) in the Archives of Neurology and Psychi-
atry. The paper itself is an exhaustive review of eight cases of
carotid related major stroke, complete with angiography
and autopsy findings.20 In this paper, Miller Fisher specu-
lated that, “one day surgeons may even devise a method to nemove the offending plaque and thereby prevent stroke.”
is prophecy, of course, was soon realized when surgeons
n three different continents attempted to do just that.
ost notable was the operation reported by Eastcott, Pick-
ring, and Rob, although theirs was an excision and graft
estruction procedure.21 The operation, as we perform it
oday, was originally described by Dr DeBakey, although
is series was not published until some years later.22 Al-
hough the relationship of carotid bifurcation atherosclero-
is as an important cause of stroke was thus established, only
ater was the nature of the pathology fully appreciated.
ascular surgeons who have opened many carotid bifurca-
ion specimens have appreciated for some time that dy-
amic plaque events are both the essence of the pathophys-
ology of stroke related to carotid stenosis, and, in fact, the
istinction that makes treatment of carotid atherosclerosis
undamentally different from treatment of coronary or
enal or mesenteric or superficial femoral artery occlusive
isease wherein relief of ischemia from vascular obstruction
s the anatomic goal of therapy. C. Miller Fisher also
escribed the important contingency of the rich collateral
irculation that exists to the brain. Thus, the removal of a
arotid bifurcation plaque was never about a “revascular-
zation” or bringing circulation to an ischemic territory
uch as we would do in other vascular territories. Rather,
he rationale of this operation has always been the removal
f a dynamic disease process wherein dynamic plaque events
ither have already, or have the potential to cause thromboem-
olic stroke.23 Where then in this paradigm was there ever
ny rationale for the luminal expansion of a necrotic plaque
ith an uncovered stent? Indeed, vascular surgeons made
he initial descriptions that certain plaque features – such as
lceration – were correlated with increased risk of stroke. In
series of publications beginning in 1969 (the year I
raduated high school), SVS 41st president and 2011 SVS
ifetime Achievement Award winner Dr Wesley Moore
escribed the ominous implications and stroke potential of
laque ulceration.24,25 Dr Moore, as national co-principal
nvestigator of the CREST trial, was invited to testify at the
MS January 2012 MEDCAC on carotid atherosclerosis. I
an assure you that his testimony was not only wise and
nformed, but also 100% consistent with SVS practice
uidelines. There is now appreciation that events such as
ntraplaque hemorrhage described by Drs Imparato and
ylie are elemental in the pathogenesis of stroke.26,27
nowledge of such pathology has opened the next arena of
laque characterization as an important component of risk
tratification in asymptomatic patients utilizing a number of
ifferent imaging techniques to provide such plaque char-
cterization. These include high-resolution ultrasound as
erified in the Asymptomatic Carotid Stenosis and Risk of
troke study reported at our meeting in 2010.28 In this
tudy, a number of clinical and plaque features, as deter-
ined by duplex ultrasound, figured prominently in stroke
rediction from previously asymptomatic lesions although
egree of stenosis was also a strong correlate of neurologic
vent risk in this study. High resolution magnetic reso-
ance imaging (MRI) has also been used for this purpose.
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Volume 56, Number 6 Cambria 1753Investigators of the cooperative High Resolution Magnetic
Resonance Imaging in Atherosclerosis of the Carotid
Artery (HIRISC) study group studied 234 patients, half of
whom were symptomatic, and noted the frequent occur-
rence of intraplaque hemorrhage overall and its strong
association with increasing degree of stenosis.29 While
stroke risk correlated with MRI demonstrated intraplaque
hemorrhage in symptomatic patients, this correlation is
hardly perfect. Finally, carotid plaque derivative phenome-
non such as transcranial Doppler-detected silent microem-
bolic phenomenon has also been championed to risk-
stratify asymptomatic patients. A meta-analysis of same
published in JVS last year re-emphasized the correlation of
both transcranial Doppler-detected micro emboli and prior
CT scan demonstrated infarction with stroke and with
increasing degrees of stenosis.30 In consideration of a treat-
ment paradigm, it is important to understand that all pa-
thology occurs in a spectrum and that the correlation of
plaque pathology with symptoms of transient ischemic
attack (TIA) and stroke is hardly perfect. A 2012 meta-
analysis collected information on a large number of ex-
planted carotid specimens, and, while establishing that
ulceration was the strongest correlate of a symptomatic
lesion, the correlation was again hardly perfect. This may
have been related to time interval between symptom onset
and carotid endarterectomy.31 Different, but related, ob-
servations were made in the large Oxford study of carotid
plaques published in 2006, which concluded that unstable
plaque features were both more common in symptomatic
versus asymptomatic plaques and that there were similar
pathologic correlates to unstable coronary plaques; dense
inflammation in the plaque correlated strongly with fibrous
cap rupture and time since stroke.32
Accordingly, it is intuitively logical that vascular sur-
geons who had been in the habit of examining these
specimens for years were horrified at the prospect of lumi-
nal expansion of an uncovered stent in the midst of such
pathology. Indeed, our inherent objection to the rationale
of this therapy has in fact been proven correct if one reviews
the available data, which I will shortly, on CAS even with
distal protection strategies. A recent study from the Emory
group is consistent with prior data using MRI-detected
periprocedural brain micro emboli. Using TCD, these in-
vestigators noted micro emboli significantly more common
with CAS versus CEA irrespective of the CAS protection
strategy.33
What then of the natural history of a carotid bifurcation
lesion? It has now been abundantly demonstrated in the
large symptomatic patient trials, that even in an era of
considerable operative morbidity (7.5% risk stroke/
death), there was a highly significant benefit for CEA versus
medical therapy in all of these trials.34 This, in turn, was
related to the prohibitive risk of stroke in patients with
symptomatic high-grade stenosis who were managed with
medical therapy alone. Accordingly, CEA for symptomatic
lesions is an indicated intervention for short-term stroke
prevention, and the risk/benefit ratio is slanted in favor of
CEA in virtually all patients. In contrast to this is the baradox that CAS at the carotid bifurcation has its highest,
nd some would say unacceptable, complication rate in the
reatment of symptomatic patients, in particular, in elderly
ymptomatic patients, especially if such treatment is carried
ut within 2 weeks of symptom onset, which of course is
he time interval when maximum benefit of CEA is
chieved. This facet is emphasized in a current report
elivered from Dr Fraedrich’s group from Innsbruck, Aus-
ria, pooling data from several of the European randomized
rials (Endarterectomy versus Angioplasty in Patients with
ymptomatic Severe Carotid Stenosis [EVA-3S], Stent-
rotected Angioplasty versus Carotid Endarterectomy in
ymptomatic patients [SPACE], and International Carotid
tenting Study [ICSS]). These investigators noted a two-fold
ncrease in stroke/death for CAS versus CEA, with a pro-
ortionally higher risk for CAS conducted within 7 days of
he qualifying event.35 Indeed, similar data had already
een reported in a number of the industry-sponsored CAS
egistries; in the Carotid Acculink/Accunet Post-
pproval Trial to Uncover Unanticipated or Rare Events
CAPTURE) Registry for either elderly or symptomatic
atients, stroke rates after CAS were essentially doubled.36
recent report from the SVS Outcomes Committee, using
ata from the SVS Carotid Registry, examined outcomes
or CEA versus CAS in patients stratified by Medicare age.
he data are powerful, with some 4000 CEA and 2500
AS procedures included; accordingly, the large numbers
llow for appropriate risk adjustment. The primary com-
osite endpoint of 30-day stroke/death/myocardial infarc-
ion was seen in 4.21% of CEA versus 7.11% of CAS
rocedures in patients 65 years – and the difference was
ighly significant, and as anticipated, was proportionally
arger in symptomatic patients, although also significant in
symptomatic patients.37
SYMPTOMATIC PATIENTS: REVISIONIST
ISTORY IS USUALLY WRONG
It is, of course, expected that the net gain achieved with
EA in asymptomatic patients would be much less impres-
ive than that seen in symptomatic patients. Accordingly,
odern natural history studies and clinical trials in asymp-
omatic patients form the basis of clinical decision-making
n such patients as articulated in the SVS practice guide-
ines.16 Two important provisos qualify current recommen-
ations and, indeed, the controversy over intervention of
ny kind in asymptomatic patients. The first of these, as
lluded to previously, is the generally accepted tenet that
etter methods are needed to “risk-stratify” asymptomatic
laques and patients. Currently, of course, we use degree of
tenosis in clinical decision-making, which I will shortly
ope to convince you that, while an imperfect surrogate, is
n fact, reasonably accurate in stroke risk prediction and, of
ourse, is easily and cost-effectively quantifiable. The second
ssue is the fashionable position (in some quarters) that mod-
rn medical therapy has so radically changed the natural
istory or stroke risk of even high-grade asymptomatic
esions, that intervention of any kind is no longer warranted –
ut more on that issue shortly.
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tomatic carotid stenoses? The modern era of such studies
dates to a full 25 years ago, when Chambers and Norris, in
a widely quoted study published in the New England
Journal of Medicine, defined stroke risk in asymptomatic
patients as substantial in patients with high-grade stenosis
and linearly associated with both degree of stenosis and
progression under observation.38 A common theme in
many of the early studies was that associated cardiovascular
events in general were also common, limiting patients’ life
expectancy and tempering somewhat enthusiasm for pro-
phylactic treatment of asymptomatic stenoses. The omi-
nous implication of lesion progression was confirmed in a
large modern series from Dr Schillinger’s group in Vienna.
Over a thousand patients with any degree of carotid steno-
sis were first assessed with two duplex studies just 7 months
apart, and then followed for a median of 3 years for clinical
events. Almost 10% of patients experienced progression
over just 7 months, and in these, stroke risk was increased
two-fold despite the fact that 70% of patients with progres-
sion were being treated with statins, which did not control
the disease.39 With the large cohort of patients available
from the North American Symptomatic Carotid Endarter-
ectomy Trial (NASCET) study, derivative information in-
dicated that the risk of stroke related to asymptomatic
stenosis was greatest in patients with the most severe de-
grees of stenosis, and secondly, that stroke was more likely
to be the first event (as opposed to TIA), thereby dynamit-
ing a strategy of wait for the first TIA. In summary, for
60% of NASCET lesions, an annual carotid-related stroke
risk of 2% per year for asymptomatic patients was the
take-home message.40 Indeed, this figure is entirely consis-
tent with the observed actuarial 5-year ipsilateral stroke risk
in the medical therapy arm of the Asymptomatic Carotid
Surgery Trial (ACST) trial.41 The most recently published
large scale prospective study of the natural history of
asymptomatic carotid stenosis was the Asymptomatic Ca-
rotid Stenosis and Risk of Stroke study published initially in
2005,42 and then with the aforementioned follow-up re-
port presented at this meeting in 2010.28 These investiga-
tors followed more than 1000 patients with moderate-to-
severe degrees of asymptomatic stenosis and, once again,
confirmed that neurologic event risk correlated strongly
with degree of stenosis and certain clinical features such as
smoking and abnormal renal function. Indeed, in patients
harboring asymptomatic stenoses wherein treatment would
be recommended by current SVS guidelines, there was a
substantial risk of TIA and stroke, which occurred in about
a 50:50 proportion at just 3 years of follow-up. The data
indicate that the combined TIA/stroke risk was substantial
at 10% at 3 years for those with a degree of stenosis such
that intervention would ordinarily be recommended. The
combination of clinical factors and duplex characterization
of the plaque could predict high- or low-risk patients, and
certainly these ultrasound observations need to be validated
in further prospective studies. These natural history studies
in aggregate indicate that, while degree of stenosis may be
an imperfect surrogate for stroke risk referable to asymp- tomatic carotid stenosis, it is, at the moment, the best we
ave, and accordingly has figured prominently in current
ractice guidelines.
The related and currently controversial topic includes
he claim that modern medical therapy has made interven-
ion for asymptomatic stenosis obsolete. Most clinicians
ecognize that there is no prospective trial data to support
his claim, but the inferences made from literature reviews
ave been widely promulgated, and it is certainly true that
here are major transatlantic differences of opinion in this
egard. Furthermore, the argument is not necessarily
ligned along medical specialty disciplines. A transatlantic
ebate published in the JVS last year emphasized the major
ifferences in approach to asymptomatic disease even
mong vascular surgeons.43 The first thing to be said is that
one would argue against the fact that modern medical
herapy has had an important overall positive effect in
troke reduction. Several meta-analyses of prospective trials
n this regard indicate that statin therapy compared with
lacebo significantly reduced both stroke risk and carotid
ntima-media thickness.44 Furthermore, in patients who
ave sustained either a TIA or stroke, the use of statin
edications has clearly been documented to significantly
educe the risk of subsequent neurologic events as demon-
trated, for example, in the Stroke Prevention by Aggressive
eduction in Cholesterol Level (SPARCL) Trial.45 Yet
hese data are quite a different matter than claiming that
ptimal medical therapy has obviated the need for interven-
ion in patients with high-grade asymptomatic carotid ste-
osis. There is little doubt that this viewpoint owes largely
o a meta-analysis published in 2009 by Dr Ann Abbott, an
cademic neurologist from Australia who is both an ardent
ritic and prolific investigator in the carotid sphere. It is
vident that Dr Abbott’s message has resonated across the
tlantic as she was one of the invited testifiers at the January
MS MEDCAC on carotid atherosclerosis, obviously cho-
en to champion the role of optimal medical therapy.18 This
eta-analysis, which I believe you will find somewhat dif-
cult to read – I certainly did – and accordingly, I have had
t analyzed by a number of experts with sophistication in
esearch methodology and statistics. After such study, my
onclusion and that of many others, is that the meta-
nalysis is flawed for several reasons. Firstly and most im-
ortantly, the studies included in the retrospective meta-
nalysis have not been corrected for threshold levels of
arotid stenosis at patient entry, or, stated differently, the
nticipated stroke risk is greatly diminished by the inclusion
f many patients with moderate degrees of carotid stenosis
herein the acknowledged risk of stroke is low, and for
hom intervention would never be recommended by cur-
ent SVS practice guidelines or in fact any other practice
uidelines.46 Oddly, the review did not include perhaps the
est contemporary data, namely the medically treated pa-
ients in the ACST trial, apparently because ACST had a
-month threshold for symptom-free status. Let us review
ome of the literature base which drives the meta-analysis
onclusions. Consider the widely quoted Second Manifes-
ations of ARTerial disease (SMART) study; less than half
h
s
p
d
p
c
l
w
o
l
s
t
m
o
d
I
C
a
p
N
i
t
a
e
l
i
s
m
t
c
t
s
P
h
e
p
y
a
(
a
2
i
P
h
f
g
c
2
s
d
t
v
p
t
JOURNAL OF VASCULAR SURGERY
Volume 56, Number 6 Cambria 1755of the approximately 200 patients considered in this cohort
had stenosis where you and I would recommend a carotid
intervention.47 Similarly, the Oxford Vascular Study, which
was published in Stroke in 2010, proudly announced that
ipsilateral stroke in patients with asymptomatic carotid
stenosis occurred in only 0.34% per year with best medical
therapy! However, once again, only a small number of
patients had a degree of carotid stenosis for which interven-
tion would be recommended; in fact only 32 and 3 of those,
or 10%, had a stroke!48 Although not available at the time
of Dr Abbott’s 2009 meta-analysis, published soon there-
after were the results of the natural history of asymptomatic
carotid stenosis in the large Reduction of Atherothrombo-
sis for Continued Health (REACH) cardiovascular regis-
try.49 REACH is an international registry of over 30,000
patients with a variety of vascular territory diseases and
provides up to 48-month clinical follow-up. This study
compared over 3000 patients with an asymptomatic carotid
stenosis in the 70% or greater range (ie, those for whom you
and I would recommend CEA, as opposed to those with-
out), and compared their natural history both in terms of
stroke risk and overall cardiovascular events. The data indi-
cated that the 1-year risk of TIA or stroke in patients with
asymptomatic high-grade carotid stenosis was 6.5%, or
two-fold that of those with lesser degrees of carotid steno-
sis; the difference was highly significant for both stroke and
other cardiovascular events as well. It is important to em-
phasize that some 70% of all patients in both cohorts were
on statin therapy at the time they were being followed in
the registry. Optimal medical therapy did not control the
disease! Finally, the ACST trial, which is the most vigorous
piece of evidence supporting CEA for asymptomatic steno-
sis, now has data reporting the benefit of CEA versus
medical therapy out to 10 years.50 This trial has been
criticized because, in the earlier years of the study, optimal
medical therapy was aspirin alone. However, as pointed out
by the ACST investigators in the later years of the trial,
more than 80% of patients were on both aspirin and a statin
agent. The 10-year data from the ACST study indicate that,
although the net gain in stroke prevention from CEA was
proportionally larger in patients not on lipid lowering ther-
apy, the net gain in stroke prevention at both 5 and 10 years
was highly significant even in those treated with modern
statin therapy, leading the ACST investigators to conclude
that “patients with tight carotid stenosis cannot have the
risk from it completely abolished by medical treatment
alone.” Despite this, it is evident that the panelists at the
January 2012 CMS MEDCAC continued to have uncer-
tainties about the relative worth of intervention versus
optimal medical therapy for asymptomatic patients.18 A
final perspective on the reluctance to accept the adequacy
of medical therapy in controlling carotid stenosis is my
personal – and I’m sure some will criticize as anecdotal –
experience. I see over 300 patients annually referred with
carotid disease and have done so for many years. The
observation of progressive carotid stenosis in patients on
optimal medical therapy is a common event in my practice.
Accordingly, we decided to study this question. Using our fealth care networks’ database, we identified nearly a thou-
and carotid arteries with duplex criteria moderate stenosis,
rogressively recorded all medical therapy/lipid panel data,
uplex, and clinical follow out to 6 years. Some 84% of all
atients were on statin medications, and over 30% of the
ohort always had a normal low density lipoprotein (LDL)
evel. The findings were striking in that, even in patients
ith optimal medical therapy as defined by LDL100 and
n aspirin and statins, such therapy failed to control both
esion progression in 40% of patients and ipsilateral TIA/
troke risk which occurred at 3%/year.51 Thus, according
o the evidence, my belief is that the claim that optimal
edical therapy will control carotid atherosclerosis is not
nly unsubstantiated but, in fact, refuted by the available
ata.
NTERVENTION: THE EVIDENCE FAVORS
EA
CEA has been abundantly demonstrated to be a safe
nd effective stroke preventive strategy in contemporary
ractice. Whereas stroke/death risks were 7.5% in the
ASCET trial, the corresponding figure was 2.6% achieved
n the CREST trial.52 Most vascular surgeons would agree
hat the current favorable results of CEA can be traced to
pplication of certain processes of care; there is now Level I
vidence attesting to the benefit of patch angioplasty at
east in the circumstance of a conventional CEA. The
mportant adjunctive roles of both anti-platelet therapy and
tatin agents have been multiply demonstrated.53 Ulti-
ately, multiple administrative database studies such as
hat from Dr Perler’s group at Hopkins,54 our own SVS
arotid registry55 and other prospective adjudicated regis-
ries such as the vascular study group of New England large
tudy,56 and finally National Surgical Quality Improvement
rogram (NSQIP) private sector data,57 indicate that CEA
as achieved a favorable position of clinical safety and
fficacy in so-called real world experience. An NSQIP re-
ort from our group was presented at this meeting a few
ears ago. As you may know, NSQIP results are adjudicated
t 30 days by independent nurse reviews. Favorable results
overall stroke/death 2.2%) for CEA in a cohort of
lmost 4000 such operations performed between 2005 and
007 were noted; furthermore, the results were equivalent
n so-called “Stenting and Angioplasty with Protection in
atients at High Risk for Endarterectomy (SAPPHIRE)
igh-risk” patients, in particular octogenarians.57 A report
rom our group presented at the Peripheral Vascular Sur-
ery Society (PVSS) program, reviewed early and late out-
omes of over 3000 CEA performed in the 15 years prior to
005. While the favorable short-term outcomes are quite
imilar to the many reports I just reviewed, the impressive
ata on long-term stroke prevention – which is of course
he goal of therapy – is worthy of emphasis.58
It is my personal opinion that elements of the CEA
ersus CAS debate have little to do with clinical efficacy or
atient safety, and the arguments are largely aligned along
he different medical specialists, which, in turn, is a struggle
or market share in the carotid arena. It is the SVS official
i
o
o
r
2
F
g
r
s
s
1
t
B
o
a
i
w
E
i
i
p
e
b
a
b
i
C
d
t
m
s
w
w
5
C
e
i
a
i
a
S
t
d
(
c
s
g
t
s
e
t
D
t
s
JOURNAL OF VASCULAR SURGERY
December 20121756 Cambriaposition that CAS has not matured to the point that it can
compete with CEA on either a safety or cost efficacy com-
parison. Of the perhaps 10 studies that have compared cost
considerations of CEA versus CAS, all but one have come
to the same conclusion as a current Oschner clinic report,
that is, that CEA is more cost-effective than CAS.59 The
negative cost implication to our health care systems of more
widespread CAS use have been reviewed elsewhere.60 It
would appear that, despite appropriately restrictive CMS
reimbursement policies, that CAS is proliferating and,
again, differentially among various medical specialists. A
report from the University of Michigan Health Policy Unit
examined physician specialty and carotid stenting use in the
Medicare database between the years 2005 and 2007. The
analysis was further stratified into a variety of hospital
referral regions, and the study compared population-based
utilization rates of CAS and 30-day outcomes for this
procedure across different hospital regions and stratified by
medical specialty. The findings indicate that cardiologists
constitute a third of the total operators, but performed
more than 50% of the procedures. Regions where cardiol-
ogists were the major operators had significantly higher
population-based rates of CAS, and the performance of
CAS was likely to be preceded by a cardiac catheterization
but not TIA/stroke!61 This led the editors of the Archives
of Internal Medicine to conclude that this proliferation of
CAS was unjustified because of definite harms, but unclear
benefits.62 We may be witnessing a repetition of what
happened in the realm of renovascular interventions. Renal
stenting grew at an alarming four-fold rate in the Medicare
population over the years 1996 to 2005, despite the fact
that there was no evidence base to support it. Stephen
Textor, a noted nephrologist from the Mayo Clinic, wrote
in the Journal of the AmericanCollege of Cardiology that the
increased rates of intervention appeared to be driven largely
by cardiologists rather than interventional radiologists or
surgeons.63
So what are the comparative clinical data for CEA
versus CAS? The SVS carotid registry, reported initially at
this forum several years ago, offers a glimpse at real world
comparative results; its outcome data are strikingly similar
to CREST and, with appropriate risk adjustment, indicates
significantly higher complication rates for CAS versus
CEA.55 There are many administrative database studies
with similar findings. A recent report from Dr Schemer-
horn’s group utilized the National Inpatient Sample data-
base, and, similar to CREST data, the safety margin of CEA
is highly significant and proportionally larger in symptom-
atic patients.64 However, focusing on asymptomatic pa-
tients, the Pittsburgh Group presented a large study utiliz-
ing California hospital discharge data. Notable in their
study was rigorous risk adjustment with propensity scoring
(possible because of large sample size) and the fact that only
asymptomatic patients were considered. In this large study
for patients treated between 2005 and 2009, stroke/death
was significantly increased for CAS versus CEA (odds ratio
2.497; P  .001).65 eWith respect to randomized clinical trial data compar-
ng CEA with carotid angioplasty and stenting, I will focus
n the two largest and most recently completed trials, since
verall they had the optimal trial design and execution. I
efer of course to the ICSS published in the Lancet in
010,13 and CREST, published just about 2 years ago.52
inally, figuring prominently in the SVS Clinical Practice
uidelines was a 2011 meta-analysis of all the available
andomized trial data conducted at the Health Policy Re-
earch Unit of the Mayo Clinic.66 The data indicate a
ignificantly increased risk of stroke (relative risk [RR]
.82) and death (RR 2.53) for CAS versus CEA. At least
hree other meta-analyses published in 2010 to 2011 in the
ritish Medical Journal, Stroke, and the Archives of Neurol-
gy have identical conclusions. So to the particulars of ICSS
nd CREST. . .
The ICSS was a prospective randomized trial compar-
ng CAS with CEA in average risk symptomatic patients. It
as carried out in 50 academic medical centers across
urope, Australasia, and Canada. Primary outcome analysis
ncluded death, stroke, and procedure-related myocardial
nfarction. This composite endpoint was noted in 8.5% of
atients undergoing CAS and 5.2% of those undergoing
ndarterectomy – a highly significant difference.13 It has
ecome fashionable among North American intervention-
lists to denigrate this and all other European studies on the
asis of possible inadequate expertise of the interventional-
sts participating in the study. Yet, the stroke/death rate for
AS noted in the ICSS study at about 8% is statistically no
ifferent from the 6% corresponding figure in the symp-
omatic patients treated in the CREST trial.67 Perhaps
ore importantly, the ICSS study was accompanied by a
ubstudy wherein pre- and post-procedure MRI diffusion
eighted imaging studies were carried out, and these data
ere reported in Lancet Neurology in 2010.68 An alarming
0% of patients (after stenting) compared with 17% (after
EA) had new MRI detected, but clinically silent micro
mbolic brain lesions. These differences were highly signif-
cant, and, although the implications of such micro emboli
re unknown, prior studies have suggested that silent brain
nfarcts were accompanied by significantly more dementia
nd other declines in cognitive functions.69 Dr Wei Zhou at
tanford University has pursued the issue of the implica-
ions of silent micro emboli brain lesions. In a report
elivered at the Society for Clinical Vascular Surgery
SCVS) a few months ago, Dr Wei Zhou of Stanford
orrelated memory decline with such micro emboli le-
ions.70 Following the ICSS trial, noted Oxford neurolo-
ist Peter Rothwell called for a moratorium on CAS, stating
hat “the routine use of stenting in patients with recent
ymptoms of carotid stenosis who are suitable for endarter-
ctomy can no longer be justified.”71
The stage was then set for CREST, which, as most in
his audience know, was led by a vascular surgeon, the late
r Robert Hobson, who made many important contribu-
ions in the carotid arena. CREST began as a study of
ymptomatic patients, but because of slow recruitment,
ventually asymptomatic patients were entered as well. The
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Volume 56, Number 6 Cambria 1757interventionalists were highly selected by an Interventional
Management Committee that eventually allowed only 50%
of the interventionalist applicants to eventually randomize
patients. Approximately, 1200 patients were randomized in
each group with a median follow-up of 2.5 years at the time
the study was published. Even with initial presentation of
the results at the American Heart Association Stroke meet-
ing in February 2010, our computers were abuzz with a
publicity blitz claiming equivalence for the two procedures
related to the fact that the composite endpoint of death,
stroke, and MI was not statistically different between the
two groups.52 Once again, as seen in prior studies, such as
the greatly flawed SAPPHIRE trial, periprocedural myocar-
dial infarction was the outcome event that swayed the
“equivalence” result. When the traditional endpoints of
combined stroke/death are compared, the incidence of
these complications following CEA was 2.6% versus 4.8%
for CAS, a difference that was highly significant. The edi-
torial accompanying the CREST publication noted that the
results were broadly consistent with that in previous trials,
namely that CAS was associated with a higher periproce-
dural risk of stroke and death, a difference that persisted at
4 years.72 The CREST trial participants have become, in a
sense, like the Democrats and Republicans, in that each
constituency has a chance to champion its particular spin on
the overall trial results. For example, our cardiology col-
leagues have argued that periprocedural MI is a valid end-
point because those who sustained such MI had inferior
4-year survival.73 Stated differently, patients with worse
coronary artery disease can be expected to die at higher
rates than those who do not harbor same. While this
consideration is intuitively logical, it is my personal opinion
that attempting to mitigate procedural outcomes by inclu-
sion of the MI endpoint is intellectually disingenuous. SVS,
in its practice guidelines, placed principle emphasis on the
traditional outcomes of stroke/death – a position echoed at
the January CMS MEDCAC meeting. The CREST data
clearly show that even a minor stroke had a significant
impact on both late functional outcome and survival, with
the 4-year mortality among those who suffered any stroke
being 20% essentially double that for stroke-free patients.
Since CAS patients had twice the stroke rate, the survival
benefit of a lower MI rate is of course negated. More
importantly, individual patient subset data are now avail-
able from CREST. As expected, the complication differen-
tial for CEA versus CAS is most pronounced in symptom-
atic patients (stroke rate CAS vs CEA: 6.0% 0.9% vs 3.2%
0.7%; hazard ratio 1.9, P  .02) and, as mentioned previ-
ously, in the elderly.52,67 CREST data indicate increasing
superiority for CEA versus CAS at an age inflection point of
approximately 70 years. It was Dr Hobson who initially,
and perhaps courageously in his own CREST trial, demon-
strated the increased risk of CAS in the elderly patients. It is
perhaps not surprising that the available data support CEA
over CAS as optimal therapy. CEA is a mature procedure
with a 60-year evolution, whereas CAS is as yet undefined
in the important elements of stent design and the optimal
protection strategies. aThus, CAS is both evolving and the results thereof in
eal world practice are unsatisfactory. A recent report pub-
ished in the Journal of the American Medical Association
ndicates a mortality (not stroke/death, but death) for CAS
n Medicare beneficiaries of nearly 2%.74 Yet, CAS is likely
o improve, and it is imperative that vascular surgeons not
nly tolerate but rather lead this evolution. Distal protec-
ion has been demonstrated to be a flawed strategy in my
iew; engineers in the audience should take heed. An
nderstanding of carotid bifurcation pathology, as re-
iewed this morning, should lead to the conclusion that the
ombination of a covered stent to truly exclude the necrotic
laque elements and a flow-reversal strategy (as opposed to
istal protection) will be the requisite elements to enable
AS to achieve a safety profile similar to CEA. This evolu-
ion has begun; the Empire Trial, led by Dr Dan Clair,
emonstrated impressive results with a stroke/death rate of
nder 3% in 245 high-risk patients treated with CAS using
ow reversal.75 Preliminary data from the Protection Sys-
em: First in Man (PROOF) trial indicate that a direct
ranscervical cut down approach to the carotid artery com-
ined with a short sheath high flow reversal system may
mprove CAS greatly by elimination of endovascular ma-
ipulation in the aortic arch.76 The advent of a multicenter
S trial testing this hypothesis is imminent; a session
omorrow morning will focus on this technology . . . and
es, there is some irony in the fact that I and my colleague
r Christopher Kwolek are the study’s principal investiga-
ors!
What then of the current evidence-based practice? How
o you advise the next patient you evaluate for carotid
tenosis? You will find a surfeit of practice guidelines pub-
ished in calendar year 2001, including our own.15,16 Re-
ently, it has been debated how such guidelines, while
pparently based on the same evidence base, can have such
isparate recommendations . . . but do they, in fact?15 The
ery scholarly multispecialty guidelines endorsed by SVS
rovide a range of guidelines in hierarchical fashion, likely
elated to a “need for consensus” among different medical
pecialists who do indeed hold very different opinions on
he role of CAS.77 Clearly, the word “alternative” is under-
tood as “equivalent” by CAS advocates, whereas the au-
hors of this guideline intended CEA as first-line therapy in
ymptomatic patients. Your SVS practice guidelines are
oth evidence-based and definitive in different patient sub-
ets; I recommend them to you as the best available re-
ource document in managing carotid disease in your prac-
ices, in particular with respect to clinical decision-making
n asymptomatic patients.
I should like to close on a philosophical note; you have
indly listened to elements of my story, so let’s recount for
moment our story. It is embodied in an Oath we all once
roclaimed, and only by remembrance of why we went into
his business, can we stay grounded in the midst of all sorts
f extraneous pressures. In particular, to the many about to
ecome vascular surgeons in the audience, I believe it is
mportant for you to hear that surgeons of my generation
re not dismayed nor downtrodden. Rather, we are opti-
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but at the same time has the ultimate in job satisfaction.
Every vascular surgeon in this room has a patient story
similar to my favorite and most inspiring patient. Al was 91
years old when he had been sent home with hospice for
treatment of severe back and groin pain secondary to a
contained ruptured thoracoabdominal aortic aneurysm. He
was still driving his car around Providence, RI, and was not
ready to call it quits; he had the will to live and underwent
an extent II thoracoabdominal aortic aneurysm replace-
ment. He shook my hand, being quite well, on the 5th
anniversary of his operation. He died just a few months ago
at age 98. Ultimate job satisfaction, indeed.
In my reflections as SVS president, I have thought of
evolutions personal, professional, and societal. All of us can
point to a few elements in our personal stories that define
who we are. I remember the first family Christmas card and
taking the boys fishing. I remember son Jay not only
catching a beautiful striper on Martha’s Vineyard, but
loving its release . . . or son Matty catching false albacore on
the Outer Banks. And my best fishing buddy, son Dan,
trying to lift stripers bigger than he was . . . or the best night
of fishing I ever had – watching an 11-year-old boy release
15 huge stripers while I never caught a one! Now, of
course, he takes me fishing, on our boat, the Sea Habit, off
the great backside of Cape Cod. I think of the father who
guided me, just as he brought his B-25 crew home across
long stretches of the Pacific with only a compass heading to
steer, and the look on his face the day I graduated medical
school. I think of patients like Senator Ted Kennedy who
inspired me, even in the face of a dismal medical prognosis
because he was guided by a “True Compass.”78 Leadership
qualities I had to think about; a few readings helped me,
and the book True North is one of them. Bill George,
currently a Harvard Business School professor but formerly
CEO of Medtronic, has written a series of books on the
qualities of successful but moral leadership of the business
world, but in fact very germane to the important role of
vascular surgeons as the leaders in vascular care irrespective
of your practice setting.79 “Your truth is derived from your
life story,” is one of the themes, and grounding the com-
pass pinnacle of leadership are our values and principles and
our knowledge of self. I call your attention to the SVS
mission statement and our core values of integrity, profes-
sionalism, and commitment to our patients. These are
vascular surgery’s “True North.” Be guided by them and
you will find professional fulfillment as I have in our won-
derful work. My fondest hope is that my tenure as SVS
president has moved our specialty and our society forward.
I thank you for your kind attention and for your ongo-
ing contributions to the Society for Vascular Surgery.
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